Clinical trial · Interventional
Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to explore the feasibility and preliminary impact of a pilot financial reimbursement intervention for women with breast cancer living in the Deep South who are eligible for a clinical trial. The main questions it aims to answer are: 1. Can we recruit and retain patients on a clinical trial to a reimbursement study? 2. What is the preliminary impact of participation in a reimbursement study on patient financial hardship? Participants will receive a monthly reimbursement to compensate for their trial-incurred expenses. Researchers will use surveys and interviews to explore the impact of receiving reimbursement on trial-related outcomes and financial hardship for participating patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Reimbursement | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients receiving reimbursement
- description
- Monthly reimbursement to offset trial-related expenses
- interventionNames
- Behavioral: Reimbursement
Primary outcomes (1)
- measure
- Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention)
- timeFrame
- 2 years
- description
- Number of patients who receive all reimbursements: 80% retention of patients Number of retained patients who patients who complete surveys: 75% of survey completion while enrolled
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants will be women with breast cancer currently enrolled in the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular AnaLysis (I-SPY TRIAL 2) at the UAB Medical Oncology Clinic. Exclusion Criteria: * Non-English speakers * Males * Females without cancer * Female cancer patients not enrolled in the I-SPY TRIAL 2
References
Publications (1)
- DERIVEDWilliams CP, Henderson NL, Jahan N, Stringer-Reasor E, Azuero A, Pisu M, Arend RC, Rocque GB. Financial reimbursement for clinical trial participation costs: a pilot feasibility study. JNCI Cancer Spectr. 2026 May 9;10(3):pkag048. doi: 10.1093/jncics/pkag048. PMID 42080701